05-Jul-2021 - Sartorius AG

Sartorius acquires majority stake in CellGenix

Portfolio expanded by cell culture components, such as growth factors, cytokines, and media

The life science group Sartorius, through its subgroup Sartorius Stedim Biotech, has acquired a majority stake in the reagent manufacturer CellGenix GmbH. The company based in Freiburg, Germany, and with a sales subsidiary near the biotechnology hub in Boston, Massachusetts USA, produces and markets cell culture components, such as growth factors, cytokines and media in GMP quality for manufacturing cell and gene therapy products.

Sartorius has initially acquired 51 percent of this company, which has been privately owned until now, for around 100 million euros in cash. At the beginning of 2023 and 2026, Sartorius plans to acquire the remaining shares of CellGenix. Founded in 1994 at the University Medical Center of Freiburg, CellGenix currently employs some 70 people and generated sales of more than 20 million euros in 2020, achieving a very significant double-digit EBITDA margin.

“CellGenix has an excellent reputation on the market and brings in high technological expertise and considerable regulatory experience in one of the fastest-growing fields of the biopharma sector. Together, we will support our customers even better in fast-tracking their drug candidates efficiently through the various steps in the development of medicines so that innovative therapies can reach patients faster,” said René Fáber, member of the Executive Board for the Bioprocess Solutions Division of Sartorius.

“For us, Sartorius is an ideal partner with a highly complementary product portfolio that will accelerate our development with its global sales team, enabling us to usher in our next phase of growth,” added Felicia Rosenthal, CEO and co-founder of CellGenix.

Sartorius plans to expand the Freiburg site substantially and to establish it as a center of excellence within the group in the areas of development and manufacture of quality critical raw materials for the cell and gene therapy market.

Facts, background information, dossiers
More about Sartorius
More about CellGenix
  • News

    CellGenix received ISO 9001:2008 certification

    CellGenix’ quality management system was certified in April 2012 on the requirements of DIN EN ISO 9001:2008 standard by the TÜV Rheinland Cert GmbH. To highlight CellGenix’ commitment to quality and service the certification of ISO 9001:2008 covers all relevant functions of the company, de ... more

    CellGenix Technologie Transfer GmbH: 15 Years of Innovation and Leadership

    2009 is a special year for CellGenix, according to the company. Cellgenix is celebrating its 15th anniversary. CellGenix was founded in May 1994 as a Spin-off from the University Medical Center Freiburg and has developed continuously ever since. 1997 the company launched the first GMP quali ... more

    CellGenix registers FDA Drug Master Files for ex-vivo CellGro® TNF-a and GM-CSF

    CellGenix has registered two new drug master files for TNF-a and GM-CSF. After filing a DMF for IL-4, this contributes further to the strategy of producing highest quality cytokines for the use in clinical ex-vivo cell culturing in connection with cell processing kits. As proposed in the ne ... more

  • Companies

    CellGenix GmbH

    CellGenix is a leading global supplier of high quality reagents and tools in the expanding markets of cell and gene therapy and regenerative medicine. CellGenix’ product portfolio includes growth factors, cytokines, serum-free media as well as closed cell culture systems (EU only). The pro ... more